# US 2016/0221927 A1 · Intermediates for macrocyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0221927 A1
- Document ID: US20160221927A1
- Status: Published application
- Kind: A1
- Application number: 14/873,056
- Filed: 2015-10-01
- Published: 2016-08-04
- Earliest claimed: 2003-06-18
- Assignees: Ocera Therapeutics, Inc.
- Applicants: Ocera Therapeutics, Inc.
- Inventors: Eric Marsault; Kamel Benakli; Hamid Hoveyda; Mark L. Peterson; Sylvie Beaubien; Luc Oullet; Carl St-Louis; Sophie Beauchemin
- Web page: https://patentgrep.com/patent/US20160221927A1

## CPC

- C07C 213/08: by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/2214: {Motilins}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 41/18: by reactions not forming ether-oxygen bonds
- C07C 67/343: by increase in the number of carbon atoms
- C07D 273/00: Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 498/04: Ortho-condensed systems
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07K 5/0821: {with the first amino acid being heterocyclic, e.g. His, Pro, Trp}
- C07K 5/0827: {containing heteroatoms different from O, S, or N}
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A process for preparing a compound of formula (G):
wherein R1 is C1-C4 alkyl and PG1 is an amine protecting group; the process comprising:
(a) contacting a compound of formula (A):
with a compound of formula (B):
in the presence of an azodicarboxylate reagent and a phosphine reagent, or in the presence of a combined Mitsunobu reagent, to form a compound of formula (C):
wherein X is halogen or triflate and PG2 is an ester protecting group;
(b) contacting the compound of formula (C) with a reducing agent to form a compound of formula (D):
(c) contacting the compound of formula (D) with a compound of formula (E):
in the presence of a palladium catalyst, optionally a copper salt and/or optionally an organic base to form a compound of formula (F):
and
(d) contacting the compound of formula (F) with hydrogen in the presence of a metal catalyst to form the compound of formula (G).

### Claim 14 (depends on 13)

The process of claim 13, wherein the compound of formula (G) is:

### Claim 15 (depends on 13)

The process of claim 13, wherein the compound of formula (B) is selected from the group consisting of:
and,
wherein PG2 is an ester protecting group.

### Claim 16 (depends on 13)

The process of claim 13, wherein X is iodine.

### Claim 17 (depends on 13)

The process of claim 13, wherein PG1 is hydrogen or a carbamate protecting group.

### Claim 18 (depends on 13)

The process of claim 13, wherein PG1 is selected from the group consisting of tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz) and allyloxycarbonyl (Alloc).

### Claim 19 (depends on 13)

The process of claim 13, wherein PG2 is an alkyl group or an alkyl group substituted with an aryl group.

### Claim 20 (depends on 13)

The process of claim 13, wherein the azodicarboxylate reagent is selected from the group consisting of diethylazodicarboxylate (DEAD) and diisopropylazodicarboxylate (DIAD).

### Claim 21 (depends on 13)

The process of claim 13, wherein the phosphine reagent is selected from the group consisting of triphenylphosphine and tributylphosphine.

### Claim 22 (depends on 13)

The process of claim 13, wherein the combined Mitsunobu reagent is a triphenylphosphine-diisopropylazodicarboxylate (DIAD) adduct.

### Claim 23 (depends on 13)

The process of claim 13, wherein the reducing agent is selected from the group consisting of an aluminum hydride and a borohydride.

### Claim 24 (depends on 13)

The process of claim 13, wherein the reducing agent is selected from the group consisting of diisobutylaluminum hydride (DIBAL-H), lithium aluminum hydride (LAH), and lithium borohydride.

### Claim 25 (depends on 13)

The process of claim 13, wherein the palladium catalyst is selected from the group consisting of dichlorobis(triphenylphosphine)palladium(II), dichlorobis(acetonitrile)-palladium(II), dichlorobis(benzonitrile)palladium(II), tetrakis(triphenyl-phosphine)palladium (0) and tris(dibenzylideneacetone)dipalladium (0).

### Claim 26 (depends on 13)

The process of claim 13, wherein the copper salt is a copper halide.

### Claim 27 (depends on 13)

The process of claim 13, wherein the copper salt is not present.

### Claim 28 (depends on 13)

The process of claim 13, wherein the organic base is selected from the group consisting of a dialkylamine, a trialkylamine and an aromatic amine.

### Claim 29 (depends on 13)

The process of claim 13, wherein the organic base is not present.

### Claim 30 (depends on 13)

The process of claim 13, wherein (c) is conducted in the presence of a phosphine.

### Claim 31 (depends on 13)

The process of claim 13, wherein the metal catalyst is palladium on carbon or platinum oxide.

### Claim 32 (depends on 13)

The process of claim 13, wherein contacting the compound of formula (A) with a compound of formula (B) in the presence of an azodicarboxylate reagent and a phosphine reagent, or in the presence of a combined Mitsunobu reagent, to form a compound of formula (C) is replaced by contacting the compound of formula (A) with a compound of formula (H):
wherein Y is a leaving group, R1 is C1-C4 alkyl and PG7 is an ester protecting group, in the presence of a base to form the compound of formula (C).

### Claim 33 (depends on 32)

The process of claim 32, wherein Y is a halogen or a sulfonate.

### Claim 34 (depends on 32)

The process of claim 32, wherein Y is selected from the group consisting of 4-methylbenzenesulfonate (tosylate), methanesulfonate (mesylate), 2-nitrobenzenesulfonate, 4-nitrobenzenesulfonate (nosylate), 2,4-dinitrobenzenesulfonate, 4-bromobenzenesulfonate (brosylate), trifluoromethanesulfonate (triflate), chloride, bromide and iodide.

### Claim 35 (depends on 32)

The process of claim 32, wherein the base is selected from the group consisting of a hydrogen carbonate salt, a carbonate salt, a trialkylamine and an aromatic amine.

### Claim 36

A process for using a compound of formula (G):
wherein R1 is C1-C4 alkyl and PG1 is an amine protecting group, to make a compound of formula (I):
